Skip to main content

Table 3 Secondary endpoints

From: An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis

 

n

0 M

6 M

Change

Mean value difference

p value

BMI (kg/m2)

12

23.7 (20.1, 26.7)

23.0 (19.7, 25.7)

− 0.4 (− 1.0, − 0.3)

0.003

Dry weight (kg)

12

64.8 (53.0, 67.2)

63.0 (51.9, 66.3)

− 1.0 (− 2.5, − 0.6)

0.028

IDWG (%)

12

4.0 (3.2, 5.2)

3.8 (2.9, 4.8)

− 0.1 (− 0.6, 0.3)

0.530

Fat ratio (%)

10

23.5 (18.4, 32.9)

20.2 (13.6, 28.4)

− 4.8 (− 8.2, − 1.7)

0.022

Fat mass (kg)

10

15.1 (9.9, 22.7)

12.1 (7.7, 18.6)

− 2.6 (− 5.5, − 1.3)

0.037

Fat free mass index (kg/m2)

10

17.1 (15.5, 17.9)

17.9 (16.5, 19.0)

0.5 (− 0.2, 1.4)

0.074

Muscle mass index (kg/m2)

10

16.3 (14.6, 17.1)

16.8 (15.6, 18.2)

0.4 (− 0.3, 1.3)

0.169

Skeletal muscle mass (kg)

10

25.5 (20.4, 28.7)

26.6 (21.9, 28.9)

0.5 (− 0.4, 1.6)

0.285

Skeletal muscle mass index (kg/m2)

10

9.4 (8.3, 10.0)

9.7 (8.8, 10.4)

0.2 (− 0.2, 0.7)

0.203

DTR-QOL score

     

 Total score

12

65.0 (35.8, 79.0)

88.0 (76.0, 93.0)

15.5 (− 1.8, 42.0)

0.023

Subscale score

     

 Domain 1

12

67.0 (38.0, 86.8)

94.5 (80.5, 99.8)

10.5 (1.5, 54.3)

0.013

 Domain 2

12

52.0 (23.8, 75.0)

81.0 (63.3, 88.8)

15.5 (− 3.8, 40.5)

0.041

 Domain 3

12

60.5 (32.3, 74.0)

98.0 (55.0, 100.0)

27.0 (− 12.8, 54.0)

0.062

 Domain 4

12

71.0 (64.0, 86.8)

77.0 (67.0, 91.0)

2.5 (− 16.8, 23.8)

0.449

DTSQ score

     

 Total score

12

26.0 (22.3, 28.8)

34.5 (31.3, 35.8)

8.0 (0.3, 12.5)

0.041

Subscale score

     

 Treatment satisfaction

12

5.0 (4.0, 5.0)

5.5 (4.3, 6.0)

1.0 (− 0.8, 2.0)

0.275

 Frequency of hyperglycemia

12

3.5 (2.3, 5.0)

1.5 (0.0, 4.5)

− 1.0 (− 4.0, 0.0)

0.073

 Frequency of hypoglycemia

12

1.0 (0.0, 2.8)

0.0 (0.0, 1.0)

− 0.5 (− 2.0, 0.0)

0.065

 Convenience

12

3.5 (3.0, 5.0)

6.0 (5.0, 6.0)

1.0 (0.0, 3.0)

0.039

 Flexibility

12

5.0 (4.0, 6.0)

6.0 (5.0, 6.0)

1.0 (− 0.8, 1.8)

0.184

 Understanding

12

4.5 (3.0, 5.0)

5.5 (4.0, 6.0)

1.0 (− 0.8, 2.0)

0.346

 Recommend

12

4.0 (3.0, 5.0)

6.0 (5.3, 6.0)

1.0 (1.0, 2.0)

0.004

 Continue

12

5.0 (3.0, 6.0)

6.0 (6.0, 6.0)

1.0 (0.0, 3.0)

0.026

  1. Data are expressed as median (interquartile range). The change indicates changes from baseline to 24 weeks
  2. BMI, Body mass index; IDWG, interdialytic weight gain; DTR-QOL, Diabetes Therapy-Related Quality of Life Questionnaire; and DTSQ, Diabetes Treatment Satisfaction Questionnaire
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us